Pinealon
← Back to LibraryOverview
Route(s): Subcutaneous
Typical vial sizes: 5, 10, 20 mg
Dosing window: Morning
Receptor / target: CNS
Properties: Not stated
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 10mg daily | Standard Khavinson protocol. Take in the morning. Repeat every 6 months. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative Titration 1: Extended Protocol (Goal: general CNS oxidative defense restoration with minimized stimulation side effects; preferred for sensitive subjects)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 5mg daily in the morning | Smoother absorption profile. Lower daily peak: better tolerated by subjects sensitive to CNS activation effects. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 2: 30-Day Graduated Protocol (Goal: sensitive subjects, first cycle, or gentlest possible pan-CNS bioregulator introduction)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-5 | 1.0 mg 1x Daily, AM | |
| Days 6-14 | 1.5 mg 1x Daily, AM | |
| Days 15-20 | 2.0 mg 1x Daily, AM | |
| Days 20-25 | 2.5 mg 1x Daily, AM | |
| Days 25-30 | 3.0 mg 1x Daily, AM |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 3: Neuroprotection Pre-Loading Protocol (Goal: CNS oxidative defense pre-loading before planned surgical anesthesia, chemotherapy, or radiation therapy with known CNS toxicity)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 (3-4 weeks pre-procedure) | 10mg 1x Daily in the morning | Full standard course before the procedure to maximize CNS antioxidant enzyme expression and mitochondrial resilience. |
| Days 1-10 (4 weeks post-procedure) | 5mg 1x Daily in the morning | Recovery course at half-dose to support CNS recovery without overloading the recovering system. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 4: Sleep Architecture Restoration Protocol (Goal: circadian rhythm normalization and sleep quality improvement in subjects with age-related circadian dysregulation; run concurrent with DSIP at bedtime for additive effect)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-5 | 2mg 1x Daily in the morning | Morning administration mandatory: resets circadian phase of pineal-hypothalamic signaling. Sleep quality improvements typically begin by days 7-10. |
| Days 6-28 | 5mg 1x Daily in the morning | Extended cycle for maximum circadian restoration. Can run concurrent with DSIP at bedtime for additive sleep architecture normalization. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 5: Parkinson's Disease Neuroprotection Protocol (Goal: substantia nigra and basal ganglia oxidative defense support; requires neurologist supervision; concurrent with Cortagen for complete CNS coverage)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 1mg 1x Daily in the morning | Requires neurologist supervision. Conservative entry is mandatory. Monitor for any change in motor symptoms. |
| Weeks 3-4 | 2mg 1x Daily in the morning | |
| Weeks 5-12 | 5mg 1x Daily in the morning | Therapeutic dose targeting iron-catalyzed oxidative stress in substantia nigra. Run concurrent with Cortagen for complete CNS coverage. Assess UPDRS motor score at baseline, week 6, and week 12. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Independent evidence
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Active CNS infections (meningitis, viral encephalitis, brain abscess): exogenous CNS bioregulator activity modulating neuronal and microglial gene programs during active brain infection could alter the CNS immune response in unpredictable ways.
- Uncontrolled seizure disorder: pan-CNS gene program modulation affecting neuronal excitability thresholds and mitochondrial energy generation in epileptic brain tissue has not been characterized; medical supervision required.
- Active intracranial malignancy: Pinealon's pan-CNS neurotrophic and cell survival-supporting mechanisms have not been evaluated in brain tumor tissue that may express CNS cell surface receptors.
- Concurrent use with narrow therapeutic index CNS drugs (phenytoin, carbamazepine, lithium, clozapine) where CNS state changes require stable pharmacological conditions: not a documented pharmacokinetic interaction but a clinical management consideration.
- Known hypersensitivity to Pinealon (Glu-Asp-Arg tripeptide) or formulation excipients.
- Pregnancy: CNS gene program modulation during fetal brain development has not been evaluated.
- Active acute stroke (within 72 hours) without medical supervision: while animal data suggests Pinealon may be neuroprotective post-stroke, the timing, dosing, and interaction with thrombolytic or thrombectomy therapy in acute stroke management requires clinical supervision.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Mild headache on cycle initiation: the most commonly reported adverse effect; occurs in a minority of subjects in the first 1-3 days; related to the shift in CNS metabolic and oxidative activity as the bioregulator effect begins; typically resolves without intervention.
- Increased dream vividness: pineal and circadian circuitry interaction produces more active REM architecture in some subjects; similar to Epithalon but typically milder.
- Mild morning energy increase: the intended cortical activation effect of morning dosing; experienced as desired enhanced alertness by most subjects; can be overstimulating in a small minority.
- Mild transient anxiety (rare): uncommon; a small subset of subjects reports mild anxious feelings in the first days of a new cycle; typically resolves after day 3-5 as CNS adaptation occurs.
- Injection site mild reaction: standard subcutaneous peptide response; minimal.
- No serious neurological adverse events documented in the Khavinson literature at standard protocol doses: the CNS safety profile across aging and neurological disease research populations is clean.
- Unknown interaction profile with modern CNS pharmacology (novel antidepressants, antipsychotics, cognitive enhancers): Pinealon's research predates modern psychopharmacology; formal interaction data does not exist.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.